JP2023512827A - 抗原結合分子およびその使用 - Google Patents

抗原結合分子およびその使用 Download PDF

Info

Publication number
JP2023512827A
JP2023512827A JP2022548123A JP2022548123A JP2023512827A JP 2023512827 A JP2023512827 A JP 2023512827A JP 2022548123 A JP2022548123 A JP 2022548123A JP 2022548123 A JP2022548123 A JP 2022548123A JP 2023512827 A JP2023512827 A JP 2023512827A
Authority
JP
Japan
Prior art keywords
antigen
alppl2
cancer
binding molecule
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548123A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512827A5 (https=
Inventor
サン，ウィリアム
オーイ パトリック タン，ブーン
ワン，ファジン
レオン ヤプ，タイ
イー ホン，シン
ワン，チェン－イ
ファン，チン－ウェン
テン リ，シュエ
フェイ ワン，カー
ドゥアン ジョナサン ウン，ジアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2023512827A publication Critical patent/JP2023512827A/ja
Publication of JP2023512827A5 publication Critical patent/JP2023512827A5/ja
Priority to JP2025172731A priority Critical patent/JP2026027248A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022548123A 2020-02-07 2021-02-05 抗原結合分子およびその使用 Pending JP2023512827A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025172731A JP2026027248A (ja) 2020-02-07 2025-10-14 抗原結合分子およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10202001139U 2020-02-07
SG10202001139U 2020-02-07
PCT/SG2021/050061 WO2021158178A1 (en) 2020-02-07 2021-02-05 Antigen-binding molecules against alppl2 and/or alpp and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025172731A Division JP2026027248A (ja) 2020-02-07 2025-10-14 抗原結合分子およびその使用

Publications (2)

Publication Number Publication Date
JP2023512827A true JP2023512827A (ja) 2023-03-29
JP2023512827A5 JP2023512827A5 (https=) 2024-02-14

Family

ID=77199411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548123A Pending JP2023512827A (ja) 2020-02-07 2021-02-05 抗原結合分子およびその使用
JP2025172731A Pending JP2026027248A (ja) 2020-02-07 2025-10-14 抗原結合分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025172731A Pending JP2026027248A (ja) 2020-02-07 2025-10-14 抗原結合分子およびその使用

Country Status (19)

Country Link
US (1) US20230080224A1 (https=)
EP (1) EP4100443A4 (https=)
JP (2) JP2023512827A (https=)
KR (1) KR20220139930A (https=)
CN (1) CN115380050A (https=)
AU (1) AU2021217919A1 (https=)
BR (1) BR112022015540A2 (https=)
CA (1) CA3170141A1 (https=)
CL (3) CL2022002114A1 (https=)
CO (1) CO2022011944A2 (https=)
CR (1) CR20220441A (https=)
DO (2) DOP2022000159A (https=)
EC (1) ECSP22061867A (https=)
IL (1) IL295291A (https=)
JO (1) JOP20220175A1 (https=)
MX (1) MX2022009709A (https=)
PE (1) PE20221781A1 (https=)
PH (1) PH12022552038A1 (https=)
WO (1) WO2021158178A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120882866A (zh) * 2022-12-21 2025-10-31 阿尔麦克探索有限公司 Alpp特异性变体抗原结合分子

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095823A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
BRPI0914251B1 (pt) * 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
JP2019131471A (ja) * 2016-05-27 2019-08-08 国立大学法人 東京大学 抗ＴＧＦ−ｂｅｔａ３抗体およびその使用
CN108088997B (zh) * 2016-11-21 2020-03-17 同济大学 利用细胞表面分子标志物鉴定人类原态多能性的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095823A1 (en) * 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAVENNI, N ET AL.: "A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer", MABS, vol. 6, JPN6025013989, 2014, pages 86 - 94, ISSN: 0005572156 *

Also Published As

Publication number Publication date
IL295291A (en) 2022-10-01
CR20220441A (es) 2022-12-14
PE20221781A1 (es) 2022-11-16
CL2024002073A1 (es) 2025-01-10
CO2022011944A2 (es) 2022-08-30
WO2021158178A1 (en) 2021-08-12
MX2022009709A (es) 2022-09-09
AU2021217919A1 (en) 2022-09-29
KR20220139930A (ko) 2022-10-17
PH12022552038A1 (en) 2023-11-29
DOP2022000159A (es) 2022-09-30
DOP2025000135A (es) 2025-07-15
JP2026027248A (ja) 2026-02-18
CL2024002074A1 (es) 2025-01-10
EP4100443A1 (en) 2022-12-14
JOP20220175A1 (ar) 2022-07-28
EP4100443A4 (en) 2024-05-15
BR112022015540A2 (pt) 2022-12-27
US20230080224A1 (en) 2023-03-16
CL2022002114A1 (es) 2023-03-03
CN115380050A (zh) 2022-11-22
ECSP22061867A (es) 2022-09-30
CA3170141A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
US20220002398A1 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
EP3928790A1 (en) Cd3 antigen binding fragment and application thereof
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
EP4393950A1 (en) Fap/cd40 binding molecule and medicinal use thereof
JP7843824B2 (ja) 抗体および使用方法
US20230045873A1 (en) ANTI-oxMIF/ANTI-CD3 BISPECIFIC ANTIBODY CONSTRUCTS
JP2026027248A (ja) 抗原結合分子およびその使用
WO2024140932A1 (en) Anti-b7h3 antibodies and methods of use
US20260028421A1 (en) Antigen-binding molecule specifically binding to gucy2c and cd3 and pharmaceutical use thereof
EA049990B1 (ru) Антигенсвязывающие молекулы против alppl2 и/или alpp и их применение
WO2025254591A1 (en) Anti-ceacam antigen-binding molecules
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2025207033A1 (en) Anti-trop2 antigen-binding molecules
JP2026505164A (ja) 抗ｃｍｅｔ抗体及びその使用方法
JP2026500752A (ja) 抗ｂ７ｈ３抗体及びその使用方法
CN120271715A (zh) 抗体及其药物偶联物和用途
CN120958028A (zh) 抗b7h3抗体及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111